Human Growth Hormone (HGH), or somatotropin, exerts its physiological effects primarily by binding to the growth hormone receptor (GHR), a member of the class I cytokine receptor family. Upon binding, HGH induces receptor dimerization, which activates associated Janus kinase 2 (JAK2) proteins. This activation initiates the JAK-STAT signaling pathway, leading to the phosphorylation of signal transducer and activator of transcription (STAT) proteins, which translocate to the nucleus to regulate the transcription of target genes. Simultaneously, HGH stimulates the synthesis and secretion of Insulin-like Growth Factor 1 (IGF-1), primarily in the liver, which acts as the major mediator of the hormone's systemic growth-promoting effects via the IGF-1 receptor (IGF-1R), activating both the PI3K/Akt/mTOR and the MAPK/ERK signaling cascades.
The impact of HGH on skeletal development is driven by its influence on growth plate chondrocytes and the process of endochondral ossification. HGH promotes the proliferation and differentiation of chondrocytes within the proliferative zone of the epiphyseal plate. Mechanistically, it stimulates the expression of C-type natriuretic peptide (CNP) and its receptor, NPR-B, which serves to counteract the negative regulatory effects of Fibroblast Growth Factor Receptor 3 (FGFR3) signaling. By modulating these pathways and activating the Wnt/beta-catenin signaling axis, HGH enhances the longitudinal expansion of bone tissue.
This process facilitates the orderly transition of cartilage to bone, effectively increasing stature by expanding the extracellular matrix and promoting the maturation of chondrocytes. In muscular and adipose tissues, HGH acts as a potent metabolic regulator by modulating cellular hypertrophy and substrate utilization. Within skeletal muscle, HGH promotes protein synthesis by activating the mTOR pathway, leading to increased amino acid uptake and myofibrillar accretion. Concurrently, it influences adipocyte metabolism by enhancing lipolysis through the upregulation of hormone-sensitive lipase while inhibiting lipogenesis.
This dual action shifts the body's metabolic state toward muscle preservation and maintenance while mobilizing stored fatty acids, resulting in improved body composition and increased cellular metabolic efficiency. The cellular effects of HGH extend to the maintenance and repair of various connective tissues, including cartilage and collagenous structures. By stimulating IGF-1 production locally and systemically, HGH promotes the synthesis of collagen and proteoglycans, which are essential for tissue structural integrity. This regenerative capacity is facilitated by the inhibition of apoptosis in target cells and the stimulation of satellite cell activation, which supports tissue repair and remodeling.
Consequently, HGH contributes to the structural density and functional capacity of both musculoskeletal and connective tissue systems. Pharmacokinetically, exogenous HGH typically exhibits a short plasma half-life, usually ranging from 15 to 20 minutes following intravenous administration, as it is cleared rapidly by the liver and kidneys. However, the subsequent induction of IGF-1 provides a more sustained biological effect, with IGF-1 circulating bound to IGF-binding proteins (IGFBPs), which extend its half-life and modulate its bioavailability at the tissue level.
The interaction between the pulsatile nature of endogenous HGH secretion and the steady-state elevation of IGF-1 ensures that target tissues receive continuous signals for growth and homeostatic maintenance, optimizing the physiological translation of the hormone’s biochemical signals into systemic tissue development.
